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Imaging of activated complement using ultrasmall
superparamagnetic iron oxide particles (USPIO) - conjugated
vectors: an in vivo in utero non-invasive method to predict
placental insufﬁciency and abnormal fetal brain development
G Girardi1,2, J Fraser3, R Lennen4, R Vontell5, M Jansen4 and G Hutchison3
In the current study, we have developed a magnetic resonance imaging-based method for non-invasive detection of
complement activation in placenta and foetal brain in vivo in utero. Using this method, we found that anti-complement
C3-targeted ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles bind within the inﬂamed placenta and foetal brain
cortical tissue, causing a shortening of the T2* relaxation time. We used two mouse models of pregnancy complications: a mouse
model of obstetrics antiphospholipid syndrome (APS) and a mouse model of preterm birth (PTB). We found that detection of C3
deposition in the placenta in the APS model was associated with placental insufﬁciency characterised by increased oxidative stress,
decreased vascular endothelial growth factor and placental growth factor levels and intrauterine growth restriction. We also
found that foetal brain C3 deposition was associated with cortical axonal cytoarchitecture disruption and increased
neurodegeneration in the mouse model of APS and in the PTB model. In the APS model, foetuses that showed increased C3
in their brains additionally expressed anxiety-related behaviour after birth. Importantly, USPIO did not affect pregnancy
outcomes and liver function in the mother and the offspring, suggesting that this method may be useful for detecting complement
activation in vivo in utero and predicting placental insufﬁciency and abnormal foetal neurodevelopment that leads to
neuropsychiatric disorders.
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INTRODUCTION
Identiﬁcation of new biomarkers to predict bad pregnancy/foetal
outcomes would be of enormous clinical beneﬁt. In particular, a
non-invasive detection of a biomarker that can identify pregnan-
cies at risk would allow determining optimal timing of delivery
and implementation of neuroprotective strategies to the mother.
Currently, there are very few methods to predict adverse
pregnancy/foetal outcomes.
Bad pregnancy outcomes have been associated with the
activation of inﬂammatory pathways,1 in particular the comple-
ment system.2,3 Pregnancy complications such as antiphospholi-
pid (aPL) antibody-induced placental pathology and foetal
growth restriction and preterm birth (PTB) has been associated
with complement activation.4–7 Complement activation has also
been related to abnormal development of the foetal brain cortex in
premature birth in mice.8 In addition, a spectrum of brain abnor-
malities and cognitive impairment has been described in infants
born to mothers affected by antiphospholipid syndrome (APS).9–11
During complement activation, C3 activation fragments (C3b/
iC3b/C3d) are covalently attached to the injured tissue. Ultrasmall
superparamagnetic iron oxide (USPIO, diameter: 5–40 nm) parti-
cles shorten the T2 and T2* relaxation time and are therefore used
as negative contrast agents in magnetic resonance imaging
(MRI).12 Moreover, by conjugating USPIOs to vectors that bind
speciﬁc molecules, the USPIO can be used to detect those
molecular targets in vivo. In the current study, we used USPIO
nanoparticles conjugated to antibodies to C3 activation products
as contrast agent of MRI to determine the presence of
complement activation/inﬂammation in the placenta and foetal
brain to predict pregnancy/foetal outcomes.
MATERIALS AND METHODS
Animals
All housing and experimental procedures were performed in compliance
with the UK Home Ofﬁce Animals Scientiﬁc Procedures Act 1986 (Home
Ofﬁce project licence number 60/4305). C57BL/6 mice (2–3-month old)
purchased from commercial vendors were used in all experiments.
Females were mated with previously isolated males. The presence of a
vaginal plug deﬁned day 0 of pregnancy.
Mouse model of PTB (PTB model). On day 15 of pregnancy, mice received
intravaginal lipopolysaccharide to induce PTB.4,8 Mice were scanned in the
morning of day 16. Scanned mice showed signs of preterm labor (vaginal
bleeding and increased expression of connexin 43—marker of myometrial
contractility—in myometrial biopsies postmortem). An age-matched group
was studied as control. Mice were killed after imaging, the foetuses were
1MRC Centre for Inﬂammation Research, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK; 2Lupus Research Unit, The Rayne Institute, King’s College
London St Thomas’ Hospital, London, UK; 3Centre for Nano Safety, Napier University Edinburgh, Edinburgh, UK; 4BHF/University Centre for Cardiovascular Science, University of
Edinburgh, Edinburgh, UK and 5Centrer for the Developing Brain, Division of Imaging Sciences and Biomedical Engineering, The Rayne Institute, King’s College London,
St Thomas’ Hospital, London, UK. Correspondence: Professor G Girardi, Women’s Health, King’s College London, St Thomas’ Hospital, London SE1 7EH, UK.
E-mail: guillerminagirardi@gmail.com
Received 28 May 2014; revised 14 July 2014; accepted 21 July 2014; published online 23 September 2014
Molecular Psychiatry (2015) 20, 1017–1026
© 2015 Macmillan Publishers Limited All rights reserved 1359-4184/15
www.nature.com/mp
weighed and the foetal brains were harvested for immunohistochemical
(IHC) studies.
Mouse model of obstetric APS (APS model). On days 8 and 12 of
pregnancy, mice were treated with intraperitoneal injections of mouse
aPL monoclonal antibodies (FB1, 1 mg). The control group received mouse
immunoglobulin g (IgG; intraperitoneal, 1 mg). Mouse monoclonal aPL
antibodies FB1 (IgG2bκ)—with anticardiolipin speciﬁcities and comple-
ment-binding capacity13—were obtained from NZW×BXSB F1 mice and
generously provided by M Monestier (Temple University School of
Medicine, Philadelphia, PA, USA).13
On day 15, the mice were subjected to MRI studies and killed after
imaging. Placentas and foetal brains were collected for IHC and
biochemical studies.
Placentas from the APS group and respective control group were analysed
for oxidative stress levels and vascular endothelial growth factor (VEGF)
content. Isoprostane 8-iso-prostaglandin F2a (signal transducer and activator
of transcription factor 8 (STAT-8)) was measured as a marker for oxidative
stress. Placental tissue was homogenised in nine volumes of 0.1 M Tris (pH
7.4) containing 1mM EDTA and 10 μM indomethacin and stored at − 80 °C in
the presence of butylated hydroxytoluene (5mg per 100ml) before being
assayed for free 8-isoprostane using a STAT-8-Isoprostane EIA kit (Cayman
Chemical, Ann Arbor, MI, USA). For VEGF content measurements, placentas
were homogenised in nine volumes of 0.1 M Tris (pH 7.4). Placental VEGF
levels were measured by enzyme-linked immunosorbent assay (R&D
Systems, Inc., Minneapolis, MN, USA). Placental growth factor (PlGF) was
measured by IHC using a speciﬁc antibody anti-PlGF (Novus Biologicals,
Littleton, CO, USA).
A group of control and APS pregnant mice were allowed to give birth,
and behavioural studies were performed in the male offspring.
Behavioural tests
Behavioural tests were performed in two male pups/mother 60 days after
birth (PND60). Elevated plus maze and open-ﬁeld tests were used to
measure anxiety levels. In the open-ﬁeld test, time spent in the centre and
number of entries to the centre were recorded. In the elevated plus maze,
time spent in the open arm and number of entries to the open arm were
calculated. Behavioural tests were not performed in the PTB model,
because the pups did not survive due to immaturity (day 16).
MRI studies
Conjugation of anti-C3-antibodies with nanoparticules and test for C3
binding. Nanomag-D-SPIO 20 nm nanoparticles (surface COOH) and
MACS separator with MS columns were purchased from Micromod
(Miltenyi Biotech GmbH, Germany). USPIO were conjugated to monoclonal
antibodies (rat IgG1) that bind speciﬁc complement activation C3
fragments C3b, iC3b and C3c deposited on tissue (clone 2/11 provided
by John D Lambris, University of Pennsylvania, Philadelphia, PA, USA).14
The conjugation was performed following an established protocol that
uses N-ethyl-N-(3-dimethyl aminopropyl) carbodiimide hydrochloride and
N-hydroxy succinimide.15 Rat IgG1, isotype control antibody, was also
conjugated to nanoparticles following the same protocol. The unconju-
gated antibodies were separated from conjugated antibodies by MACS
column. The ﬁnal products of conjugation were suspensions without
precipitate. The amount of iron conjugated was determined by potassium
thiocyanate method using FeCl3-6H2O as a reference.16
The presence of anti-C3 antibodies or isotype control antibodies on the
surface of conjugated USPIO was conﬁrmed by measuring protein content
by Bradford methodand the amount of antibody in all preparations was
32–40 μgmg− 1 nanoparticles.
The functionality/binding of USPIO-conjugated anti-C3 antibodies was
conﬁrmed by IHC. MRL/lpr mice develop lupus nephritis with deposition of
C3 activation fragments in the kidney.17 Kidney frozen sections from MRL/
lpr mice17 and C3− /− mice (negative control) were incubated with USPIO-
conjugated anti-C3 antibody (dilution 1:100) and unconjugated anti-C3
antibody (dilution 1:100). A secondary antibody ﬂuorescein isothiocyanate
(FITC)-conjugated (Santa Cruz Biotechnology, Inc., Dallas, TX, USA, dilution
1:400) was used to develop the IHC reaction.
MRI protocols. Animals from the APS and PTB model groups and respective
controls (mIgG-treated mice and untreated age-matched controls) received
the USPIO particles (0.5mg per mouse) (unconjugated, conjugated with
anti-C3 antibody and conjugated with rat IgG1) intravenously (volume
o100 μl) as a bolus (administration time, 2–3 s) 12–14 h before the imaging
session. After the imaging sessions, mice were killed, and placentas and
foetal brains were isolated for IHC and biochemical studies.
All MRI experiments were performed using a 7-Tesla horizontal bore
Nuclear Magnetic Resonance spectrometer (Agilent Technologies, Yarnton,
UK), equipped with a high-performance gradient insert (60mm inner
diameter), maximum gradient strength 1000mTm− 1. The mice were
anesthetised with 1.8% isoﬂuorane in oxygen/air (50/50, 1 litre min− 1) and
placed in a cradle (Rapid Biomedical GmbH, Rimpar, Germany). The rectal
temperature and respiration rate were monitored throughout the
experiments, and body temperature was maintained at 37 °C with a heat
fan. A 33-mm diameter birdcage volume coil (Rapid Biomedical GmbH)
was used for radio frequency transmission and signal reception. For
anatomical assessment, respiration-gated T2-weighted fast spin echo
images (echo train length of 8) of 1-mm slice thickness in a sagittal
orientation were collected with the following parameters: repetition time
(TR)≈3000ms depending on the respiration rate; effective echo time=48
ms; 24 slices, ﬁeld of view=35× 35mm2; matrix = 192× 192, 2 signal
averages. For T2* mapping and calculation of T2* relaxation times, image
acquisition used a gradient echo, multiple echo, untriggered pulse
sequence of 10 images weighted in T2*; TE = 1.38, 2.94, 4.50, 6.06, 7.62,
9.18, 10.74, 12.30, 13.86 and 15.42ms; TR = 100ms. From the anatomical
images corresponding sagittal slices encompassing the most representa-
tive anatomies of interest (foetal brain, placenta, liver, muscle and kidney)
were selected with a 35× 35mm2 ﬁeld of view containing a 192× 192
acquisition matrix (in-plane resolution= 0.182× 0.182mm2). Slice thickness
was 1 mm with 14 signal averages.
MRI data analysis. All images were processed and T2* maps generated
with the VnmrJ software (Version 3.2A, Agilent Technologies). For each T2*
map, regions of interest were drawn in each organ of interest making sure
to stay well within the boundaries of the respective organ and the mean
regions of interest T2* values were used as quantitative measures of T2*
relaxation times (ms) for each tissue type.
IHC studies
Foetal brains were harvested in the APS and PTB models and respective
controls and incubated overnight in paraformaldehyde 4% with 10%
sucrose for cytoprotection. Foetal brain tissue was then frozen in Optimal
Cutting Temperature compound and cut into 10-μm sections. IHC studies
were performed to evaluate the expression of microtubule associated
protein-2 (MAP-2; Sigma Aldrich (St Louis, MO, USA) dilution 1/100)—a
marker of intact neuronal cell bodies—and neuroﬁlament 200 (NF-200;
Sigma Aldrich, dilution 1/400)—to evaluate dendritic and axons structure.
Neurodegeneration was measured using Fluoro-Jade B (Millipore, Millerica,
MA, USA), a polyanionic ﬂuorescein derivative which sensitively and
speciﬁcally binds to degenerating neurons.18 Ten views per slide were
analysed in each experimental condition.
Mice from the PTB and APS groups and respective controls that did not
receive USPIO injections were killed after MRI, and placentas and foetal
brains were processed for IHC. Frozen sections were stained for complement
deposition, using monoclonal anti-C3b, -iC3b and -C3c antibodies (clone
2/11 provided by John D Lambris, University of Pennsylvania).14
To study whether USPIO-anti-C3 antibodies cross the placenta and the
foetal blood–brain barrier (BBB), IHC studies were performed. FITC-
conjugated antibodies to rat IgG1 were used to visualise the presence of
USPIO-anti-C3 antibodies in the placentas and foetal brains in APS and PTB
mice after the MRI studies. IHC studies to detect the presence of aPL
antibody FB1 were also performed in the placentas and foetal brains from
APS mice. PlGF was determined by IHC in frozen sections from placentas in
APS and mouseIgG-treated mice. Confocal double-labelled microphoto-
graphs were captured using a Leica Microsystem (Leica, Milton Keynes, UK)
with settings appropriate to the ﬂuorophores present.
Isolation of foetal cortical neurons
Cortical neurons from day 16 foetuses were isolated as previously
described8,19 and cultured on coverslips coated with laminin/polylysin
(5 × 105 cell cm− 2). Control cells extend their neurites and establish
synapses in culture after 10 days in culture and thus represent an
accessible model to study cortical brain development.19 After 7 days in
culture (7 DIV), neurons were exposed to aPL antibody FB1 or control
antibody (mouse IgG). Formation of neuritic networks in each experimental
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group was evaluated on 10 DIV by IHC using βIII tubulin antibodies after
ﬁxation with paraformaldehyde 4%.
Effects of USPIOs on pregnancy
To study the potential effects of USPIOs in pregnancy, foetal and placental
weight at day 16 was recorded in control and USPIO-treated mice after MRI
imaging. Placental VEGF and isoprostane 8-iso-prostaglandin F2a STAT-8
content were measured by enzyme-linked immunosorbent assay as
described above. Another group of control and USPIO-treated mice were
allowed to give birth and time of delivery was recorded. To investigate
clearance of USPIO nanoparticles in these groups, T2* maps for the liver
were generated. Liver function tests were performed by measuring hepatic
enzymes alanine transaminase (ALT) and aspartate transaminase (AST)
with commercial kits (Abcam, Cambridge, UK) in the mother during and
after pregnancy and in the offspring.
Statistical analysis
Data are expressed as mean± s.d. Statistical differences between groups
were determined using one-way analysis of variance with subsequent two-
tailed Student’s t-test.
RESULTS
Conjugation of USPIOs to anti-C3 antibodies does not affect
antibody-binding capacity
After conjugation, the reactivity of anti-C3 antibodies was veriﬁed
by IHC. USPIO-conjugated anti-C3 antibodies were used to detect
C3 deposition in glomeruli from MRL/lpr mice (Figure 1ai) and
compared with unlabelled anti-C3 antibody (Figure 1aii). Using
USPIO-conjugated anti-C3 antibodies as primary antibodies and
FITC-conjugated secondary antibodies, C3 deposition was
detected in the kidneys from MRL/lpr mice. USPIO-conjugated
anti-C3 antibodies detect C3 (Figure 1ai) in a similar manner to
unconjugated anti-C3 antibodies (Figure 1aii), indicating that the
binding capacity of the antibody is preserved. In addition,
USPIO-conjugated anti-C3 antibodies did not bind to the kidneys
from C3-deﬁcient mice (Figure 1bi) that do not express C3, as
shown by IHC using unconjugated anti-C3 (Figure 1bii), indicating
that the binding of USPIO-conjugated anti-C3 antibodies to C3 is
speciﬁc.
Figure 1. Binding capacity of ultrasmall superparamagnetic iron oxides (USPIOs) conjugated to anti-C3 antibodies compared with
unconjugated antibodies. Passage of USPIO-conjugated antibodies through the placenta and foetal blood–brain barrier. (ai) USPIO-
conjugated anti-C3 antibodies were used to detect C3 deposition in renal glomeruli from MRL/lpr mice. USPIO-conjugated anti-C3 antibodies
were used as primary antibodies and ﬂuorescein isothiocyanate (FITC)-conjugated as secondary antibodies. Positive staining was found in the
kidneys from MRL/lpr mice. (aii) Detection of C3 deposition in the kidneys from MRL/lpr mice using unlabelled anti-C3 antibodies. (bi) USPIO-
conjugated anti-C3 antibodies did not bind to the kidneys from C3-deﬁcient mice (bii) Immunohistochemical studies using unlabelled anti-C3
antibodies demonstrate the absence of C3 deposition in renal glomeruli from C3-deﬁcient mice (C3− /− ), indicating that the binding of
USPIO-conjugated anti-C3 antibodies to C3 is speciﬁc. (c) Immunohistochemical studies, using FITC-conjugated anti-rat immunoglobulin G1
(IgG1) performed after the magnetic resonance imaging studies show the presence of USPIO-conjugated antiC3 antibodies in the placental
labyrinth of antiphospholipid syndrome (APS) mice (c), foetal brain from APS mice (d) and in foetal brain from preterm birth mice injected
with USPIO-anti-C3 (e). The respective controls are mIgG-treated mice and age-matched mice. The ﬁrst and third panels (left to right) in panel
c show the placenta in APS- and mIgG-treated mice. Original magniﬁcation × 40. The second and fourth panels correspond to the labyrinth
area. Original magniﬁcation × 20. Microphotographs (a–e) represent one of 4–5 similar experiments. The brain diagram shows the area of the
cortical brain where the microphotographs were taken. The placental diagram shows the location of the labyrinth within the mouse placenta.
USPIO to predict bad pregnancy and foetal outcomes
G Girardi et al
1019
© 2015 Macmillan Publishers Limited Molecular Psychiatry (2015), 1017 – 1026
USPIO-conjugated anti-C3 antibodies cross the placenta and the
foetal BBB
IHC studies performed after the MRI studies showed the presence
of USPIO-conjugated anti-C3 antibodies in the placenta of APS
mice (Figure 1c) and in the foetal brain of APS (Figure 1d) and PTB
mice injected with USPIO-anti-C3 (Figure 1e) compared with their
respective controls (mIgG-treated mice and age-matched con-
trols). These data demonstrate that anti-C3 antibodies conjugated
to USPIO cross the placenta and the foetal BBB. Within the
foetal brain and placenta, most of the USPIO-conjugated anti-C3
antibodies were found in the cortex and the labyrinth,
respectively.
Injection of USPIO-conjugated anti-C3 caused a signiﬁcant
reduction in T2* relaxation time in foetal brains in PTB and APS
mice indicating increased C3 deposition
We previously demonstrated abnormal cortical cytoarchitecture
and increased neurodegeneration in the foetal brain in the mouse
model of PTB.8 Cortical foetal brain abnormalities were associated
with increased complement split product C5a levels. Interestingly,
here we found increased C3 deposition in the foetal cortical brain
in PTB mice (Figure 2a) compared with age-matched control. A
signiﬁcant reduction in T2* time—indicative of positive binding of
USPIO-conjugated anti-C3—was observed in vivo in the foetal
brains in utero in PTB mice compared with age-matched
control and PTB mice that received USPIOs or control Ab-USPIOs
(Figure 2b). Macrophages, present in inﬂamed tissue, may
phagocytose USPIOs and thus cause a T2* signal diminution. T2*
time in the placentas in APS and the foetal brains in APS and PTB
mice injected with USPIOs was not different from USPIO-treated
control mice, indicating that phagocytic cells do not have a
signiﬁcant role in the decreased T2* times observed in APS and
PTB mice treated with USPIO-conjugated anti-C3-treated anti-
bodies. Thus the MRI data suggest that the T2* signal diminution
in APS and PTB mice is due to the presence of C3. T2* maps are
shown in Figure 2c. As previously described, diminished NF-200
and MAP-2 staining was also observed in the cortex of foetal
brains in PTB mice compared with age-matched control
(Figure 2a), indicative of a disruption of cortical dendritic and
axonal cytoarchitecture. In addition, increased neurodegeneration,
measured by FluoroJade B, was also observed in the foetal cortical
brain in PTB mice compared with age-matched control (Figure 2a).
A similar association between complement deposition and
abnormal cortical foetal brain development was observed in the
APS model. First, we demonstrated that aPL antibodies FB1 are
able to cross the BBB and reach the foetal brain. Indeed, FB1
antibodies were found in the foetal brain cortex by IHC (Figure 3a).
T2* values in APS mice that received USPIO-anti-C3 were lower
than APS mice that received only USPIO or mouse IgG-treated
mice that received USPIO-anti-C3 (Figure 3b). This suggests that
complement C3 deposition is observed in the foetal brains in the
APS model. IHC studies conﬁrmed the presence of C3 deposition
in the foetal brain cortex in APS mice (Figure 3c). Similar to the
PTB, increased C3 deposition and abnormal cortical brain
development were observed in the brains of foetuses exposed
to aPL in utero. The diminished NF200 and MAP-2 staining
observed in the foetal brains in APS compared with mouse-IgG
Figure 2. Increased C3 deposition, signiﬁcant reduction in T2* relaxation time and abnormal foetal cortical brain cytoarchitecture in preterm
birth (PTB) mice. (a) Confocal microscope photomicrographs demonstrating increased C3 deposition, decreased NF-200 and MAP-2 staining
and increased neurodegeneration in the foetal brains in PTB mice compared with age-matched control. Microphotographs represent one of
the ﬁve similar experiments. The brain diagram shows the area of the cortical brain where the microphotographs were taken. (b) Signiﬁcant
reduction in T2* time was observed in vivo in the foetal brains in utero in PTB mice treated with ultrasmall superparamagnetic iron oxide
(USPIO)-anti-C3 compared with age-matched control and PTB mice that received USPIOs or control Ab-USPIOs. *Statistically signiﬁcant
compared with control mice injected with USPIO-anti-C3 (Po0.05), to preterm mice that received USPIO (Po0.05) and SPIO-Ctrl antibody
(Po0.05) and preterm untreated mice (Po0.05). (c) T2* maps of maternal abdomen in a PTB mouse and age-matched control injected with
USPIO-anti-C3 antibodies. The dashed ovals show the amniotic sacs containing the foetuses. Microphotographs represent one of 4–5 similar
experiments.
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treated mice suggest an abnormal cortical neuron development
(Figure 3d). In addition, increased neurodegeneration was
observed in the foetal brains from APS mothers (Figure 3d).
Neurotoxic effects of aPL antibodies
To conﬁrm the detrimental effects of aPL on the developing foetal
brain, we studied isolated cortical neurons from day 16 foetuses.
IHC procedures determined that most cultured cells (495%)
express βIII tubulin (Figure 4a), protein associated with cortical
neurons and not found in glial cells. These cells extend their
neurites and establish synapses becoming mature neurons after
10 days in culture. To study the effects of aPL on developing
neurons in vitro, we exposed the cells on day 7 (7 DIV) to FB1
antibody. The neuronal culture media includes foetal calf serum as
a source of complement. As a quantitative measure of neuronal
injury during neuronal development, we analysed the growth of
projections emanated from the neuronal cell bodies. At day 10,
long axons were observed in cultured control cortical neurons
(incubated with mouse IgG) (162 ± 32 μm), whereas the length of
axons in aPL-exposed neurons was considerably reduced after the
addition of aPL to the media on 7 DIV (39 ± 11 μm) (Figure 4a).
Incubation of cortical neurons with aPL in the absence of
complement C3 (C3− /− serum) prevented aPL-induced neuro-
toxic effects. Long axons were observed in cultured cortical
neurons incubated with FB1 plus C3-deﬁcient serum, suggesting a
role for complement in aPL-induced neurotoxicity.
Behavioural abnormalities in the offspring in the APS model
The open-ﬁeld test and the elevated plus maze test showed
increased anxiety-related behaviour in the offspring from APS
mice (Figures 4b and c). Offspring from APS mothers show a signi-
ﬁcant decrease in the percentage of time spent in the centre and a
signiﬁcant reduction in the number of entries into the centre in
the open-ﬁeld test (Figure 4b) when compared with control group
and mice born to mouse IgG-treated mothers) consistent with
anxiety-related behaviour. In the elevated plus maze, offspring
from APS mothers showed a signiﬁcant decrease in the number of
times they explore the open arms and the time spent in the open
Figure 3. Antiphospholipid (aPL) antibodies bind to foetal brain. Increased C3 deposition, signiﬁcant reduction in T2* relaxation time and
abnormal foetal cortical brain cytoarchitecture in antiphospholipid syndrome (APS) mice. (a) Immunohistochemical studies demonstrating
positive staining for aPL antibody FB1 in foetal brain tissue from APS mice. Microphotographs represent one of four similar experiments. The
brain diagram shows the area of the cortical brain where the microphotographs were taken. (b) T2* values in APS mice that received
ultrasmall superparamagnetic iron oxide (USPIO)-anti-C3. Asterisk (*): T2* values were statistically signiﬁcantly lower in APS mice injected with
USPIO-anti-C3 compared with APS mice that received only USPIO or mouse immunoglobulin G (IgG)-treated mice that received USPIO-anti-C3
(Po0.05 for all the comparisons). (c) Confocal microscope photomicrographs demonstrating the presence of increased C3 deposition in foetal
brains in APS mice compared with mIgG-treated control mice. Microphotographs represent one of ﬁve similar experiments. The brain diagram
shows the area of the cortical brain where the microphotographs were taken. (d) Confocal microscope photomicrographs demonstrating
NF200 and MAP-2 staining in the foetal brains in APS mice compared with mouse-IgG treated. Diminished NF200 and MAP-2 staining suggest
an abnormal neuronal development. Increased neurodegeneration is also observed in foetal brains in APS mice. Microphotographs represent
one of ﬁvesimilar experiments. The brain diagram shows the area of the cortical brain where the microphotographs were taken.
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arms was also less when compared with mice born form control
and mIgG-treated mothers (Figure 4c). Locomotor activity did not
change among groups.
Decreased T2* relaxation time in placentas from APS mice that
received anti-C3-USPIO
Complement activation and placental inﬂammation are crucial
events in obstetric APS.20 Decreased T2* time was observed in
placentas from APS mice that received USPIO-anti-C3 antibodies
compared with APS mice treated with USPIO alone and control
mouse IgG-treated mice injected with USPIO-anti-C3 (Figure 5a).
The fast pin echo MRI coronal view (Figure 5b) clearly shows a
placenta in APS mice. Increased C3 deposition in placentas from
APS mice was also detected by IHC (Figure 5c). Abundant C3
deposition was observed in the labyrinth, crucial placental
structure responsible for gas and nutrient exchange between
the mother and the foetus. Increased C3 deposition in placentas
from APS mice was associated with increased oxidative stress—-
measured as STAT-8 content—(Figure 5d) and decreased levels of
VEGF (Figure 5e) and PlGF (Figure 5f). In addition, intrauterine
growth restriction and decreased placental weight were observed
in foetuses from APS mice compared with control mice treated
with mouse IgG (Figure 5g).
USPIO administration did not affect liver function and pregnancy
outcomes
It has been described that administration of silica and titanium
dioxide nanoparticles (0.8 mg per mouse, nanoparticle diameter:
35 and 70 nm) causes pregnancy complications.21 In the present
study, mice treated with USPIO nanoparticles (0.5 mg per mouse,
diameter: 20 nm) had normal pregnancy outcomes. USPIO-treated
mice gave birth at term like control groups (pregnancy length
(days): USPIO (n= 4): 20.2 ± 0.8 vs control (n= 6): 20.6 ± 0.5)). In
addition, foetal and placental weights at day 16 in USPIO-treated
mice were not different from control (Figure 6a). Oxidative stress
levels (STAT-8 levels) and VEGF concentration in placentas from
USPIO-treated mice were not different from control mice (Figures
6b and c). T2* values in placentas from control untreated-mice
were similar to USPIO-treated mice (T2* (ms): control (n= 6):
10.2 ± 4.3 vs USPIO (n= 4):9.1 ± 5.7), suggesting that USPIO
nanoparticles do not accumulate in the placenta. Interestingly, a
lower T2* value was found in the maternal liver of USPIO-treated
mice when compared with control (T2* (ms): control (n= 6):
13.7 ± 2.2 vs USPIO (n= 4):4.4 ± 2.6*, *Po0.01), suggesting that
USPIOs are cleared by the liver. Measurement of hepatic enzymes
AST and ALT activity showed that USPIOs do not affect liver
function. AST and ALT activity during pregnancy and after
pregnancy in USPIO-treated mice were not different from control
females (Figure 6d).
DISCUSSION
PTB is a major public health problem.22 More than 15 million
babies are born prematurely worldwide. When babies are born
before they are fully developed, they face many serious medical
problems, such as neurodevelopmental impairment.23 Unfortu-
nately, in the majority of the cases of PTB, there are few tests that
can be employed to predict if a foetus is at risk for the
development of brain injury. In the APS, foetuses exposed to
aPL antibodies in utero are also at risk. In APS, miscarriage, foetal
death and placental pathologies are common.20,24,25 There is
growing evidence about the transplacental passage of aPL
antibodies, and a spectrum of brain abnormalities and cognitive
impairment has been described in infants born to mothers
affected by APS,9–11 suggesting that exposure to aPL in utero
Figure 4. Antiphospholipid (aPL) antibody FB1 induces neurotoxicity in vitro. Behavioural studies in the offspring of antiphospholipid
syndrome (APS) mice. (a) Neuritic network formation in isolated foetal cortical neurons incubated with aPL and mouse immunoglobulin G
(IgG). Incubation with aPL antibodies induced a signiﬁcant decrease in total length of b-III-tubulin-positive neurites, compared with untreated
neuronal cells, suggesting abnormal development of cortical neurons. In the absence of complement component C3 (serum from C3-deﬁcient
mice), aPL did not affect neuritic network formation. Cells were identiﬁed as neurons by positive BIII tubulin staining. Five to six cortical
neurons preparations were used for each experimental condition. (b) Offspring from APS show a signiﬁcant decrease in the percentage of
time spent in the centre and a signiﬁcant reduction in the number of entries into the centre in the open-ﬁeld test when compared with
control group (*Po0.05) and mice born to mouse IgG-treated mothers (*Po0.05) consistent with anxiety-related behaviour. Five to six mice
were studied in each experimental group. (c) In the elevated plus maze, offspring from APS mothers showed a signiﬁcant decrease in the
number of times they explore the open arms and the time spent in the open arms was also less when compared with mice born from control
(*Po0.05) and mIgG-treated mothers (*Po0.05). Locomotor activity did not change among groups. Five to six mice were studied in each
experimental group.
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affects foetal brain development and thus might induce
behavioural and cognitive problems later on in life. In our studies,
we showed that, during pregnancy, complement-activating aPL
antibody FB1 crosses the placenta and the BBB reaching the foetal
brain and affecting its normal development. This is in agreement
with the literature that shows that maternal antibodies have direct
access to the developing brain during gestation.26
Inﬂammation, in particular complement activation, is a common
mediator in the pathogenesis of PTB and obstetric APS.2,4,5,7,27 In
this study, using nanotechnology, we successfully developed a
non-invasive in utero method to determine the presence of
complement activation/inﬂammation in the placenta and foetal
brain to predict pregnancy/foetal outcomes in PTB and pregnan-
cies complicated with APS.
USPIO particles are magnetic resonance contrast agents that
give rise to a signiﬁcant shortening of T2 and T2* relaxation
time.12 USPIOs can be conjugated to vectors directed to speciﬁc
targets and detected by MRI in vivo. In this study, we conjugated
USPIOs to monoclonal antibodies to complement C3 split
products (C3b, iC3b, C3c) to detect complement activation
in vivo in utero by MRI. Importantly, we were able to show that
USPIO-conjugated anti-C3 antibodies cross the placenta and the
foetal BBB reaching the foetal brain. That IgG antibodies cross the
placenta and the foetal BBB is in accordance with other
studies.28,29 In addition, the BBB is developing during gestation
allowing antibodies to have direct access to the brain during
gestation.30
Injection of USPIO-conjugated anti-C3 caused a signiﬁcant
reduction in T2* relaxation time—indicative of increased C3
deposition—in the placentas and foetal brains from abnormal
pregnancies. Increased C3 deposition in the placenta and foetal
brains was associated with abnormal cortical foetal brain
development and placental abnormalities in pregnancies com-
promised by PTB and APS. In the APS model, increased C3
deposition in placenta was associated with placental insufﬁciency
characterised by increased oxidative stress, decreased levels of
proangiogenic factor VEGF and PlGF and decreased placental and
foetal weight. This suggests that measuring C3 deposition using
Figure 5. Decreased T2* relaxation time in placentas from antiphospholipid syndrome (APS) mice that received anti-C3-USPIO (ultrasmall
superparamagnetic iron oxide). (a) Decreased T2* time was observed in placentas from APS mice that received USPIO-anti-C3 antibodies
compared with untreated APS mice (*Po0.05), APS mice treated with USPIOs alone (*Po0.05), APS mice injected with USPIO-Ctrl AB
(*Po0.05) and control immunoglobulin G (IgG)-treated mice injected with USPIO-anti-C3 (*Po0.05). (b) Fast pin echo magnetic resonance
imaging coronal view showing a placenta in APS mice. (c) Increased C3 deposition in placentas from APS mice compared with control mIgG-
treated mice, detected by immunohistochemistry. Microphotographs represent one of ﬁve similar experiments. The placenta diagram shows
the area of the labyrinth where the microphotographs were taken. (d) Increased oxidative stress—measured as signal transducer and activator
of transcription factor 8 content in placentas from APS mice compared with mIgG-treated mice. n= 4–5 mice/group. (e) Decreased levels of
vascular endothelial growth factor in placentas from APS mice compared with mIgG-treated mice. n= 4–5 mice/group. (f)
Immunohistochemical detection of placental growth factor in placentas from APS- and mIgG-treated mice. (g) Intrauterine growth restriction
and decreased placental weight in foetuses from APS mice compared with control mice treated with mouse IgG. n= 4–5 mice/group.
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USPIOs and MRI during pregnancy might be a useful method to
predict placental pathologies, intrauterine growth restriction and
foetal brain abnormalities.
Generally, T2 relaxation time diminishes when blood ﬂow is
diminished and oxyhaemoglobin levels are low. Considering the
increased oxidative stress observed in placentas in APS mice, we
expected to see a diminished T2 signal in untreated APS-mice
compared with control mice. Although T2* signal values in
placentas from APS mice were slightly lower than in mice treated
with control antibody, they did not reach statistical signiﬁcance.
This data suggest that placental blood ﬂow is not signiﬁcantly
compromised in APS.
C3 deposition in the foetal brain was associated with
cytoarchitectural cortical neurons abnormalities in PTB and APS
mice. We previously demonstrated that complement activation
has a detrimental role in cortical brain development in preterm
foetuses and in vitro using cultured isolated foetal cortical
neurons.8 Here we also showed that the neurotoxic effects of
aPL on neuritic network formation in vitro is also dependent on
complement activation. The role of complement in brain injury
remains controversial, and most of the previously published
studies were performed in adult animals. In favour of the
deleterious effects of complement in foetal brain injury, a study
showed that C3 is depleted in the blood of neonates who
subsequently develop cerebral palsy.31 In addition, complement
depletion has shown to improve cerebral blood ﬂow and
neurological function after ischaemia in adult rats32 and reduced
post ischaemic cerebral infarct volume and atrophy in neonatal
rats.33 Other studies showed that complement inhibition failed to
prevent brain injury caused by thromboembolic stroke34 and
hypoxia–ischaemia35 in adult animals. A recent study showed that
hypoxic/ischaemic injury in neonates is ameliorated in mice that
overexpress C3a.36 However, in this study, hypoxic/ischaemic
injury was induced at postnatal day 9, and only white matter
injury was evaluated. Our studies demonstrate an association
between increased foetal brain C3 deposition and abnormal
cortical foetal brain development in day-16 foetuses in utero.
Interestingly, we were able to correlate cortical brain abnormal
development with behavioural changes in the APS mice. Increased
anxiety was observed in the offspring of APS mice, suggesting that
in utero exposure to aPL antibodies causes abnormal cortical
development and suggests that C3 might be a footprint for
adverse foetal outcomes. Our studies associating abnormal foetal
cortical development with increased anxiety in the offspring of
APS mice are in agreement with the literature that shows that,
during prefrontal cortex brain injury, the neural networks involved
in the regulation of anxiety are compromised.37 Interestingly, it
has been described that adult mice with APS showed a pattern of
moving along the edges of the open ﬁeld rather than randomly
through the centre.38 A similar behaviour was observed in the
offspring of APS mothers in our studies.
Although C3 deposition in the foetal brains and placentas in
APS can be simply explained by the activation of the classical
pathways by aPL antibodies,5,27 the cause of C3 activation in the
foetal brains in PTB is not fully understood. We previously
proposed that C5a generated in the cervix during preterm labour
can reach the utero and the foetal brain. We can speculate that
C5a—generated during spontaneous preterm labour—could
activate neurons to release reactive oxygen species, which further
cleave C3 creating a complement activation feedback cycle.
It was previously demonstrated that placental complement
deposition is associated with adverse pregnancy outcomes in APS
in humans and mice.20 Interestingly, complement deposition in
human placentas in APS was found in the villous tree, vascular bed
site for feto-maternal exchange, equivalent to the labyrinth in
mice.20 Here we show that increased placental complement
Figure 6. Effects of ultrasmall superparamagnetic iron oxide (USPIO) on pregnancy outcomes and liver function in the mother and offspring.
(a) Foetal and placental weight at day 16 in USPIO-treated mice were not different from control untreated mice. n= 4–5 mice/group. (b)
Oxidative stress levels (signal transducer and activator of transcription factor 8 levels) in placentas from USPIO-treated mice were not different
from control mice. n= 4–5 mice/group. (c) Vascular endothelial growth factor levels in placentas from USPIO-treated mice were not different
from control mice. n= 4–5 mice/group. (d) Hepatic enzymes (alanine transaminase and aspartate transaminase) activity in the serum in
mothers during pregnancy (–day 14) and postpartum (21 days) and offspring in USPIO-treated and control mice.
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deposition is predictive of placental insufﬁciency resulting in
intrauterine growth restriction in APS.
A recent study also demonstrated the usefulness of superpara-
magnetic iron oxide-conjugated nanoparticles to detect
complement activation in vivo.39 In this study, the authors
successfully showed complement deposition in glomerulonephri-
tis in mice by using SPIO particles conjugated to human
complement receptor 2.39
In conclusion, using this in utero non-invasive method, we
found that complement activation is a footprint for cortical foetal
brain abnormalities and behavioural changes in pregnancy
complicated by APS and of abnormal neuronal cytoarchitecture
in the cortical brain in PTB. In addition, increased complement
deposition in placentas predicted placental abnormalities and
intrauterine growth restriction in the mouse model of APS.
Contrary to a previous publication, showing that nanoparticles
cause pregnancy complications,18 our data show that USPIO
administration to pregnant mice is safe and no placental/foetal
abnormalities are observed. The MRI studies show that the
USPO nanoparticles used in this study—of smaller size than the
ones used in the previous study—are rapidly cleared through the
liver. Normal liver function was observed in USPIO-treated
mothers (during pregnancy and after pregnancy) and in their
offspring when compared with control animals, emphasizing
that USPIO are not hepatotoxic. That USPIOs did not affect
pregnancy outcomes suggests that this non-invasive in utero
method to detect complement activation using anti-complement
antibodies conjugated to USPIOs might be safe to use in humans
and might help predict bad pregnancy/foetal outcomes in
pregnancies at risk. The identiﬁcation of foetuses with neurode-
velopmental and/or placental abnormalities during pregnancy
would allow the possibility of giving the mother neuroprotective
strategies to modulate inﬂammation and prevent abnormal foetal
autcomes.
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